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 ABSTRACT AND KEYWORDS 
  
Under the clinical impression that COPD is associated with low 
testosterone levels, we investigated this association. We selected 100 male 
COPD patients and categorized them according to GOLD criteria. Serum 
testosterone levels of these patients were measured. We sought a significant 
association between severe COPD and testosterone levels. 34 of the 100 patients 
had low testosterone levels.The conclusions of our study were i) patients in 
GOLD stage IV had higher probability of having low testosterone levels ii) 
Patients had higher risk of low testosterone levels with decreased oxygen 
saturation iii) Patients showed a tendency of decreasing BMI with increasing 
severity iv) Patients on long term glucocorticoid treatment had higher chances 
of having low testosterone levels.  
             Thus low testosterone levels are frequent in COPD with increasing 
severity. Testosterone replacement therapy has already been tried in this setting. 
Further studies are required before routine recommendations can be made. 
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INTRODUCTION 
Testosterone is the most important androgen in males. Biosynthesis of 
testosterone occurs mainly in the adult Leydig cells. The daily testicular 
output of testosterone is between 3-10 mg. 
 Being the principal circulating androgen from the adult testes, 
testosterone has a negative-feedback action on pituitary secretion of 
gonadotropins. The biologically active fraction of testosterone is the free 
circulating form which constitutes about 2% of the total circulating form, the 
remainder being bound to SHBG (60%) and albumin (38%). 
 Testosterone levels are decreased in a variety of disease states. The 
mechanisms which contribute to this state vary. This state of hypogonadism 
in males causes further impairment of quality of life in addition to that caused 
by the underlying disease state. 
 Low testosterone levels in chronic diseases have an independent effect 
on mortality which has been shown by studies. Trials on Testosterone 
replacement therapy in these diseases have been done with encouraging 
results. 
 Chronic Obstructive Pulmonary disease (COPD) is rampant in our 
country. The mortality rate in severe COPD remains high. Low testosterone 
level is one of the important contributors to this mortality. Hence an attempt 
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has been made to study the serum Testosterone levels in male COPD patients 
at the Institute of Internal Medicine, Madras Medical College. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
AIMS AND OBJECTIVES 
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AIMS & OBJECTIVES 
 
1) To study the prevalence of low Testosterone levels in male COPD 
patients. 
2)  To correlate the prevalence of low testosterone levels in COPD with 
disease duration and severity. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
REVIEW OF LITERATURE 
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REVIEW OF LITERATURE 
 
CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
Definition: 
 COPD encompasses a group of diseases rather than a single disease. 
(Chronic Bronchitis, Small Airways disease &Emphysema) 
 The characteristic of COPD, airflow limitation is a result of small 
airway disease and destruction of lung parenchyma. 
 Chronic Bronchitis is clinically defined as “the presence of chronic 
productive cough on most days for three months, in each of two consecutive 
years after ruling out other causes of chronic cough”. The three forms of 
chronic bronchitis are 
1) Simple bronchitis 
2) Chronic or Recurrent mucopurulent bronchitis 
3) Chronic Obstructive bronchitis 
 Emphysema is defined as “abnormal, permanent enlargement of the 
distal air spaces (distal to terminal bronchioles ) accompanied by destruction 
of their walls without obvious fibrosis”. 
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 Small airways disease/ Obstructive bronchiolitis is due to 
inflammation, squamous cell metaplasia and/ or fibrosis in airways less than 
2 mm diameter. It is one of the earliest changes that occur in smokers1.Its 
contribution to the airflow obstruction increases as the disease progresses2. 
 The relative contribution made by airway abnormalities or distal 
airspace enlargement to airflow limitation in a COPD individual is difficult to 
determine. Thus the term COPD was introduced in the early 1960s to 
describe patients with largely irreversible airflow obstruction, due to a 
combination of airway disease and emphysema. 
 
EPIDEMIOLOGY: 
 COPD is an important disease of much global importance with regards 
to many factors such as the disease prevalence, burden of morbidity & 
mortality. The disease prevalence could increase in the near future. 
 
GLOBAL SCENARIO: 
The worldwide prevalence of COPD in adults > 40 years of age is 
about 9-10%3,16. COPD is the third leading cause death & the fifth leading 
cause of DALYs worldwide5. 
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 The COPD prevalence varies among different countries3. These 
variations in prevalence could be attributed to different methods of diagnosis 
& classification14. The COPD prevalence rates are much higher when 
spirometry is used for diagnosis when compared to clinical symptoms 
alone15. 
 The BOLD (Burden of Obstructive Lung Disease ) study involved 
9425 individuals from 12 different sites. Post bronchodilator spirometry 
testing was used to assess the prevalence of COPD in this study. The overall 
prevalence of GOLD stage ≥ II was 10.1% ( men-11.8% , women- 8.5% ). 
This study brought out regional differences in COPD prevalence worldwide. 
Among men the figures varied from as high as 22% in Cape Town, South 
Africa to 9% in Reykjavik, Iceland. The prevalence among women was no 
exception with 4% in Hannover, Germany to 17% in Cape Town, South 
Africa17. 
 The PLATINO study was conducted in South American countries to 
assess the COPD burden. This study also used post bronchodilator spirometry 
for finding out the prevalence of COPD. The study showed that the COPD 
prevalence in the 5 Latin American countries studied was 14.3% ( GOLD 
stage ≥ II – 5.6% )18. Similarly a Chinese study showed that the prevalence of 
COPD varied from 5-13% in different provinces of China19. 
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INDIAN SCENARIO: 
An Indian study done recently to study the prevalence of Asthma, 
Chronic bronchitis & respiratory symptoms concluded that the prevalence of 
chronic bronchitis in adults > 35 years was around 3.49%3. 
          The contribution of India to the total global mortality of COPD is quite 
significant with the recent figures showing about 102.3/ 1 lac population4. 
COPD has already overtaken Malaria & Tuberculosis as a leading cause of 
morbidity & mortality in India4. The burden of COPD is not uniformly 
distributed across India. The recently conducted INSEARCH study enrolled 
85105 men & 84470 women from 11 rural & 12 urban areas. It showed that 
the prevalence of COPD in Mumbai (Western India ) was 1.1% whereas in 
Trivandrum ( Southern India ) it was an alarming 10%3. The study concluded 
that the national burden of COPD to be 14.84 million3. 
          The distribution of COPD varies among various subpopulations & 
within subpopulations. Many factors influence the disease distribution. For 
example, COPD is a disease of older age groups & is rare in young 
individuals unless he/she has a strong genetic predisposition like alpha-1 
antitrypsin deficiency8.There is a strong male preponderance in COPD. This 
could be due to increased rates of tobacco smoking among men particularly 
in India6,7,8. The male:female ratio & the smoker:non-smoker ratio in India 
are not as high as it is in the western countries6,9. The above mentioned 
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differences could largely be due to the widespread usage of biomass fuel for 
cooking & indoor air pollution10-13. Passive smoking (tobacco smoke 
exposure from household males) is also a contributory factor to the above 
difference6. Although the INSEARCH study showed variations according to 
geographic locations in COPD prevalence, a study conducted by Jindal et al 
showed that the sex differences in COPD prevalence were similar across the 
country9. 
AETIOLOGY: 
 COPD results from the interplay of genetic & environmental factors. 
ENVIRONMENTAL FACTORS: 
1) Tobacco smoke: 
Smoking is the most important risk factor for developing COPD3,4. 
Previously it was thought that only 10-20% of smokers develop clinically 
significant COPD. Now it has been proved that it is a gross underestimate. 
The risk of developing COPD is directly related to the total tobacco exposure. 
Despite smoking being the most important risk factor for developing COPD, 
about 10% of COPD patients are non-smokers. Thus it is obvious that 
although smoking is a crucial factor, additional factors play a major role in 
the development of COPD. 
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 One of the most important evidences that link smoking with COPD 
comes from the United Kingdom. A study was conducted between 1953 & 
1967 in the UK among doctors & the general population. All the participants 
were asked to record their smoking habits. The mortality rate due to chronic 
bronchitis in the doctor’s wing fell by a staggering 24% whereas in the 
general wing it fell by a meagre 4%. The above difference in mortality rates 
was attributed to decreased smoking among doctors as compared to the 
general population. 
              Effects of smoking on the respiratory system are 
a) Increase in prevalence of respiratory symptoms 
b) Abnormalities in lung function 
c) Increased rate of FEV1 decline per annum 
d) Greater mortality rate compared to non-smokers 
 
2) Passive Smoking: 
 Passive smoking can lead to the development of respiratory symptoms 
& airflow limitation (Environmental tobacco smoke)20,21. There is evidence 
that increased amount of environmental tobacco smoke exposure in 
childhood could lead to a decrease in the peak FEV1 level that can be 
achieved in adulthood. It is a well known fact that antenatal smoking is 
10 
 
coupled with low birth weight & smoking by either parent increases the 
incidence of respiratory illnesses in the first three years of life. These 
associations suggest that environmental tobacco smoke could have an effect 
on the immune system. 
 
3) Outdoor air pollution: 
 This is a major problem in industrialized regions & metropolitan cities. 
Among the outdoor air pollutants, particulate pollutants (eg. Sulphur di-
oxide)play a major role in the exacerbation of airways disease & COPD23. 
The association between decline in lung function & outdoor air pollution has 
been shown by various longitudinal studies22. Photochemical air pollutants 
(eg. Nitrogen di-oxide, Ozone) are more of an important factor in Asthma 
rather than COPD. 
 
4) Indoor air pollution: 
This is a more common setting in the under developed countries. 
Overcrowding, usage of biomass fuel for cooking are important causes of 
indoor air pollution10-13,24. These factors are more important in the 
development of COPD in women particularly in cultures where female 
smoking is not common. 
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5) Chronic bronchopulmonary infection: 
 Bronchopulmonary infections play a crucial role in the natural course 
of COPD. Prophylactic antibiotics do not appear to protect against recurrent 
COPD exacerbations due to infections. This has been proved by various 
studies some of which have been conducted as early as the 1960s & 70s. 
Earlier it was thought that respiratory infections lead to acute decline in lung 
function in COPD patients which was totally reversible on clearance of the 
infection. More recent data have challenged this view and they have 
suggested that recurrent bronchopulmonary infections lead to progressive 
worsening of FEV125. 
 Symptoms of cough & sputum production in the age group of 20-35 
years are more common among those who have had childhood history of 
severe lower respiratory illness. This association between childhood 
respiratory illness & adulthood decline in lung function is probably due 
multiple reasons such as passive smoking, low socioeconomic status, 
overcrowding, exposure to high amounts of pollution. 
 
6) Occupation: 
 Causal relationship between occupational dust exposure and COPD is a 
generally accepted fact. In this setting, smoking is often a confounding factor 
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due to the high prevalence of smoking habits among people engaged in these 
occupations. Various longitudinal studies have shown the link between 
progressive worsening of FEV1 and occupational dust exposure26-28.Among 
patients with respiratory symptoms or pulmonary function abnormalities 
consistent with COPD, 10-20% of cases are attributed to long term 
occupational dust exposure. The government of United Kingdom brought 
COPD under the list of diseases considered for compensation in miners 
following accumulating evidence of association between coal dust exposure 
and COPD. Others occupations that are associated with increased COPD risk 
include welding, Shipyard work, Cadmium exposure etc. Increased incidence 
of emphysema among workers exposed to cadmium has been shown by 
studies29. 
 Not all occupational dusts are equally effective in promoting the 
development of COPD. For example, a study done by Oxman et al showed 
that workers involved in gold mining had a triple fold risk of developing 
COPD when compared to those working in coal fields26. This difference 
could be due to the increased silica content in gold mines. 
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7) Diet: 
 There is growing evidence that some of the dietary habits could be 
linked to the development of COPD. A study done in Britain has brought out 
the correlation between dietary consumption of fresh fruits and ventilator 
function, both in smokers and non-smokers. There is evidence that low 
plasma ascorbic acid levels are associated with increased risk of developing 
COPD. This could be due to increased incidence of pneumonias among 
Vitamin C deficient individuals30. 
 
8) Socioeconomic factors: 
 Low socioeconomic status is associated with the development of 
COPD7,31. The cause is multifactorial such as overcrowding, indoor air 
pollution etc. 
 
HOST FACTORS: 
1) Genetic factors: 
 Genetic susceptibility to COPD has been shown by the increased 
familial risk of acquiring significant airflow limitation in smoking siblings of 
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patients with severe COPD. Genetic studies have revealed various genes that 
are linked to the development of COPD. Some of the genes are 
a) Microsomal epoxide hydrolase-1 
b) Tumour necrosis factor ( TNF ) 
c) Transforming growth factor β ( TGFβ ) 
Genetic linkage analysis has revealed various regions in the genome that 
could contain COPD susceptibility genes eg. Chromosome 2q. However the 
strongest genetic link with COPD is the alpha1 antitrypsin deficiency. 
 
2) Gender: 
 Traditionally COPD has been more common among men when 
compared to women. However in recent times this gender gap has narrowed. 
This could possibly be due to the increased female smoking. It has been 
proposed that females are more prone to the ill effects of tobacco smoke. But 
gender as a risk factor for COPD is a question that is far from resolved. 
 
3) Atopy& Airway hyperresponsiveness: 
 In the 1960s, the “Dutch hypothesis” was proposed. It stated that 
“smokers with chronic, largely irreversible airways obstruction and subjects 
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with asthma shared a common constitutional predisposition to allergy, 
airway hyperresponsiveness, and eosinophilia”.It has been shown by various 
studies that smokers have higher serum IgE levels & eosinophil counts when 
compared to non smokers32. Asthmatic patients have the same pattern33 but 
the levels are much higher when compared to COPD patients. Atopic status 
shows no variability among smokers and non-smokers& whether airway 
hyperresponsiveness is a cause or consequence of COPD is debatable. 
 
4) Factors acting in gestation: 
 Mortality from chronic pulmonary diseases varies inversely with birth 
weight & weight at one year of age. Thus impaired growth in utero, 
particularly impaired lung growth drastically increases the chances of an 
individual developing COPD. 
 
OTHER CONSIDERATIONS: 
Chronic mucus hypersecretion: 
 Smokers have a higher incidence of respiratory symptoms and mucus 
production. Cessation of smoking leads to the cessation of mucus 
hypersecretion in about 90% of cases. The British hypothesis stated that 
“Chronic airflow limitation resulted from the development of chronic mucus 
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hypersecretion as a result of recurrent bronchial infection”.This hypothesis 
was tested in the studies conducted by Fletcher &Peto among London’s 
working men. This study showed that there was a progressive decline in 
FEV1 among smokers but it failed to demonstrate a correlation between 
declining FEV1 and the degree of mucus hypersecretion. However a study 
conducted in Copenhagen between 1976 & 1994 showed that mucus 
hypersecretion was associated with increased rates of hospital admission and 
a progressive decline in FEV1. 
 
Morbidity/ Use of health resources: 
 COPD has a huge impact on the usage of health care resources 
including outpatient visits, hospitalization & ICU care. The economic burden 
imparted by COPD is more than twice that of Asthma. The frequent 
exacerbations in COPD patients further affects the quality of life.  
 In the European Union, respiratory diseases account for 6% of the total 
direct health expenditure and COPD accounts for 56% of it. The cost of care 
of COPD and the severity of the condition are directly related. 
 Years of living with disability (YLD) can be calculated to estimate the 
morbidity burden of the disease. The global figure is around 1.68 YLD/1000 
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populations, which represents 1.8% of all years of living with disability, with 
a major effect in men. 
 
Mortality: 
 In USA and Europe, COPD is the fourth leading cause of death. COPD 
is a growing epidemic worldwide. By the end of 2020, COPD could well be 
the third leading cause of death worldwide. 
 There are wide international variations in COPD mortality. These 
variations cannot be entirely attributed to differences in diagnostic patterns, 
smoking habits etc. COPD is a contributing factor in various other causes of 
death. Thus the true mortality due to COPD could well be far higher than the 
current estimates34. 
Natural history & Prognosis: 
 COPD is generally progressive, particularly if the exposure to the 
noxious agent continues. However, the natural history of COPD is highly 
variable among individuals. Cessation of noxious agent exposure (eg. 
Smoking) could possibly halt disease progression. 
 The average decline of FEV1 in non-smokers is 20-30 ml/year. In 
smokers there is an accelerated rate of FEV1 decline at 50 ml/year. In 
addition lower respiratory tract illnesses promote FEV1 decline in active 
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smokers35. The study done by Fletcher and colleagues among working men in 
London gave valuable insights into the course of COPD. The study was a 
follow up study of 8 years duration. The study showed that it was possible to 
pick up susceptible cigarette smokers early in mid life by a reduction in 
FEV1. A tracking effect was suggested by the study (ie) persistence of 
individuals in the same percentiles over subsequent years irrespective of 
whether they were in the highest or lowest FEV1 percentiles initially. 
 
Geneticallysusceptibleindividual 
     Smoking 
Accelerated decline in FEV1 
 
Severe airways obstruction 
 
 The rate of decline in FEV1 varies during the progression of the 
disease. There is a tendency for slower declines in FEV1 in advanced disease 
when compared to mild disease. 
 The strongest predictors of survival in COPD patients are 
a) Age 
b) Baseline FEV1 
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 The five year  mortality rate in COPD patients with FEV1 ≤ 30% is 
more than 50% and the relationship between post bronchodilator FEV1 and 
survival is even stronger. Other predictors of survival that have been 
suggested are the 6 minute walk distance36 and exercise capacity37. Other 
unfavourable prognostic factors are 
a) Severe hypoxaemia 
b) Low CO transfer 
c) Raised pulmonary artery pressure 
d) Weight loss 
Pathology: 
 The pathological changes that occur in the respiratory system in COPD 
patients are complex. Basically, changes occur in three compartments. They 
are 
a) Large airways 
b) Small airways 
c) Alveoli 
 The relative contribution of the three compartments in the airflow 
obstruction in a given patient is a subject of considerable study40,44. The 
correlation between the pathologic changes and both clinical & functional 
patterns of disease is generally poor. There is still no unity of thought 
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regarding the cause of fixed airway obstruction in COPD (ie) due to either 
inflammation & scarring in small airways or to the loss of support for the 
airways due to loss of alveolar walls. Although the pathological changes in 
COPD occur in the above mentioned compartments, in a given patient 
abnormalities may coexist in all the three compartments rather than in one 
compartment. 
 The characteristic features of COPD are 
a) Poorly reversible airflow obstruction 
b) Abnormal inflammatory response in the lungs43 
 The abnormal inflammatory response in lungs is due to innate and 
adaptive immune responses to noxious agents. Pulmonary inflammatory 
response occurs in all cigarette smokers but an abnormal or increased 
immune response occurs in those who develop COPD43. The results of an 
amplified immune response are tissue destruction, mucus hypersecretion, 
small airway inflammation and fibrosis. These pathological changes result in 
air trapping & progressive airflow limitation due to increased impedance to 
airflow in small airways & increased pulmonary compliance. 
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Chronic Bronchitis: 
 The cause of mucus hypersecretion41 that occurs in chronic bronchitis 
is due to  
a) Increase in the volume of submucosal glands. 
b) Increase in the number of goblet cells 
c) Change in the goblet cell distribution in the surface 
epithelium 
 In normal circumstances, submucosal glands are confined to the larger 
bronchi, decreasing in size and number in the smaller bronchi and not present 
in the bronchioles. In the setting of chronic bronchitis, the submucosal glands 
hypertrophy with inflammatory cell infiltration. 
 In a similar way, in healthy individuals who have never smoked, goblet 
cells are more commonly seen in the proximal airways with declining trends 
towards the distal airways and total absence in the respiratory bronchioles. 
The mucociliary escalator mechanisms are poorly developed in the distal 
airways. In smokers,goblet cells increase in number and extend peripherally. 
Thus great quantities of mucus are produced in the distal airways where 
mucociliary mechanisms are poorly developed. In addition, smokers exhibit 
poor mucociliary function. 
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 The role of inflammation in chronic bronchitis has been studied using 
bronchial biopsies. There is a clear evidence of bronchial wall inflammation 
in this condition. Activated T lymphocytes are found in the bronchial walls of 
these patients. This is a feature that is shared also by asthma. But in contrast 
to asthma, the T cells seen in chronic bronchitis are of CD8 subtype rather 
than CD4 and macrophages are also seen in addition to the CD8 cells. 
Neutrophils are predominantly seen infiltrating the glands which increases in 
number as the disease progresses45,46. 
 Bronchial biopsies in a few number of studies have shown that there 
are increased number of eosinophils in the bronchial walls45. These numbers 
are small when compared with acute exacerbations of asthma. In addition, 
eosinophils seen in asthma usually degranulate whereas in chronic bronchitis 
they do not. 
  In patients with chronic bronchitis, increased intraluminal airspace 
inflammation has been shown by bronchoalveolar lavage and sputum studies. 
Neutrophils and macrophages42,47 are the predominant inflammatory cells 
seen in this type of inflammation. Air space inflammation might not be 
totally reversible even after smoking cessation. 
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Emphysema: 
Emphysema is airway enlargement distal to terminal bronchioles. It is due to 
the destruction of walls without obvious fibrosis.  
According to the enlarged airspace distribution, emphysema has been 
classified into two major types. 
a) Centriacinar ( Centrilobular ) emphysema ( enlarged 
airspaces are clustered around terminal bronchioles 
initially) 
b) Panacinar ( Panlobular ) emphysema ( airspace 
enlargement distributed throughout the acinar unit ) 
 Centriacinar emphysema is the common type in COPD. This type is 
commonly seen in the upper zones of upper and lower lobes. The panacinar 
variant is more prominent in the lung bases but it can be found anywhere in 
the lungs. Alpha1 antitrypsin deficiency is associated with the panacinar type. 
With regards to smoking, it has a clear association with centriacinar 
emphysema than with panacinar emphysema48. 
 Periacinar( Paraseptal/distal acinar ) is an airspace enlargement along 
the edge of  the acinar unitwhere it lies adjacent to a fixed structure like a 
blood vessel or pleura. This type is less common than the other two types. It 
carries little clinical significance. In rare circumstances if there is extensive 
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periacinar emphysema in the subpleural region it can lead on to 
pneumothorax. 
 Emphysematous lesions are small ( < 1 mm diameter ) during the early 
stages of the disease. In due course these lesions may progress to large 
lesions called bullae48. A bulla is a locally over distended area of emphysema. 
It is usually more than 1 cm size. Bullous disease is not confined to COPD. 
 The tubular integrity of normal bronchioles and small bronchi is 
maintained via attachments to the walls of alveoli. In emphysema this 
arrangement is disrupted which leads to distortion and irregularity of airways. 
 Similar to the inflammatory cell infiltration seen in the airways, 
changes are seen in the alveolar walls. Even though absence of fibrosis is a 
prerequisite for the diagnosis of emphysema, some amount of fibrosis is seen 
in the terminal bronchioles due to respiratory bronchiolitis that occurs in 
COPD patients. 
EXTENT OF AIRWAY INFLAMMATORY RESPONSE38,39: 
COPD STAGE AIRWAYS WITH MEASURABLE 
NEUTROPHILS(%) 
GOLD 0 67 
GOLD I 55 
GOLD II & III 84 
GOLD IV 100 
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COPD STAGE AIRWAYS WITH MEASURABLE 
MACROPHAGES ( % ) 
               GOLD 0                 54 
               GOLD I                 66 
               GOLD II & III                 73 
               GOLD IV                 92 
 
COPD STAGE AIRWAYS WITH MEASURABLE 
EOSINOPHILS ( % ) 
               GOLD 0                 25 
               GOLD I                 33 
               GOLD II & III                 29 
               GOLD IV                 32 
 
COPD STAGE AIRWAYS WITH MEASURABLE 
CD4 CELLS ( % ) 
              GOLD 0                 63 
              GOLD I                 87 
              GOLD II & III                 77 
              GOLD III & IV                 94 
 
COPD STAGE AIRWAYS WITH MEASURABLE 
CD8 CELLS ( % ) 
             GOLD 0                  85 
             GOLD I                  80 
             GOLD II & III                  88 
             GOLD IV                  98 
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COPD STAGE AIRWAYS WITH MEASURABLE 
B CELLS ( % ) 
             GOLD 0                   7 
             GOLD I                   8 
             GOLD II & III                 45 
             GOLD IV                 37 
 
Bronchiolitis / Small airways disease44: 
 This concept was introduced by Hogg, Macklem and Thurlbeck. They 
showed via experiments that the major site of airway resistance in COPD is 
the small airways. Small airway inflammation is an early change seen in 
asymptomatic cigarette smokers50. These changes are associated with no 
symptoms initially and considerable amount of change can occur in the 
airways without causing spirometry changes. The pathological changes found 
in small airways49 are 
a) Inflammatory cell infiltration in airway wall 
b) Mucus and cells in the lumen 
c) Goblet cell hyperplasia 
d) Airway wall fibrosis50 
e) Squamous cell metaplasia 
f) Mucosal ulceration 
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g) Increased amount of muscle 
h) Pigmentation 
  
 Bronchiolitis is a early feature of COPD. Studies conducted in resected 
lung specimens show that there is a change in the inflammatory response 
with disease progression. These changes are caused by immune responses to 
noxious agent exposure for long periods. It has been found that later in the 
course of the disease there are increased numbers of B cells and lymphoid 
follicles around the bronchioles. This could represent an autoimmune 
response to chronic lower respiratory tract infection. 
 
Pulmonary Vasculature: 
 Pulmonary vascular changes are an early feature of COPD. These 
changes progress through the course of the disease. The end result is 
pulmonary hypertension and right ventricle dysfunction51. 
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INITIAL CHANGES: vessel wall thickening, endothelial dysfunction52 
 
 
PROGRESSION: increased vascular smooth muscle, inflammatory cell 
infiltration of vessel 52wall (CD8 cells & macrophages) 
 
 
LATER STAGES: collagen deposition, emphysematouschanges in 
alveolarcapillary bed52 
 
 
PULMONARY HYPERTENSION 
 
Pathogenesis: 
 Inflammation is invariable in the lungs of smokers. It is a protective 
response against inhaled toxins. Individuals in whom the inflammatory 
response is amplified develop COPD. This abnormal inflammation in COPD 
results in tissue destruction, impaired defence & repair mechanisms43. The 
factors that are key to the pathogenesis of COPD are 
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a) Amplified inflammation 
b) Protease – Antiprotease imbalance 
c) Oxidative stress 
 
Noxious agent 
 
Airway inflammation – CD8 cells, Macrophages, Monocytes 
 
Irreversible airflow limitation 
 
Inflammatory cells and mediators: 
 The inflammatory cells that are recruited to the lungs secrete a number 
of cytokines that amplify the inflammatory response. Some of the important 
mediators are53-56 
a) Leukotriene B4 
b) Chemokines - IL-8 
c) Proinflammatory cytokines – TNFα, IL-1β, IL-6 
d) Growth factors – TGFβ 
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Protease – Antiprotease imbalance: 
 α1- antitrypsin deficiency associated early onset emphysema and 
Papain induced emphysema in rats when instilled into lungs were 
instrumental in understanding the pathogenesis of COPD. The above two 
observations laid the foundation for the formation of protease – 
antiproteasehypothesis57 which states that “under normal circumstances the 
release of proteolytic enzymes from inflammatory cells that migrate to the 
lungs to fight infection does not cause lung damage because of inactivation of 
these proteolytic enzymes by an excess of inhibitors”.If there is an excessive 
load of enzymes or an absolute or functional deficiency of inhibitors an 
imbalance develops. This imbalance causes uncontrolled enzyme activity 
leading to pulmonary alveolar wall connective tissue destruction resulting in 
emphysema. Some of the important protease – antiprotease combinations are 
Neutrophil elastase –α1- antitrypsin , serine proteinases –α1- antitrypsin , 
Cathepsin G – Secretory leukoprotease inhibitor , Cysteine proteinases – 
Cystatins , Proteinase 3 – Elafin and Matrix metalloproteinases 8,9,12 – 
TIMP 1-4. 
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α1-antitrypsin / α1- protease inhibitor: 
 Alpha1-antitrypsin is a polymorphic glycoprotein. It is the most 
important factor contributing to serum’s antiprotease activity58. It is produced 
in the liver. It is an acute phase reactant.The active site of this protein has a 
methionine-serine sequence upon which its activity depends heavily. 
 The relationship between α1- antitrypsin deficiency and early onset 
emphysema was first described by Laurell and Eriksson in 1963. The 
deficiency is transmitted in an autosomal recessive fashion and over 75 
biochemical variants have been identified. 
PHENOTYPE FREQUENCY EMPHYSEMA  RISK 
MM 86 % nil 
MZ 3 % Nil 
MS 9 % Nil 
ZZ 0.03 % Present 
SZ 0.2 % Present 
SS 0.25 % Nil 
 
 Inability to raise α1- antitrypsin levels during acute phase responses 
leads to undeterred proteolytic damage of pulmonary tissue. Cigarette 
smoking acts as a cofactor in this setting by creating an oxidative stress 
which inactivates the remaining functional enzyme. 
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 The prevalence of α1- antitrypsin deficiency is between 1 in 2700 to 1 
in 5000. Development of emphysema is not invariable in these patients. 
Although studies have pointed out that there is a progressive decrease in 
FEV1 in these patients, individuals show large variations. However the life 
expectancy is greatly decreased if these individuals smoke59. 
 
Oxidative stress: 
Cigarette smoke                               Inflammatory cells 
 
        Oxidants                                       Reactive oxygen & nitrogen species 
 
       Reduced endogenous            
       antioxidant responses 
 
 
  The effects of oxidative stress60-62 are 
a) Antiprotease inactivation 
b) Increased mucus production 
c) Proinflammatory gene activation 
d) Augmentation of inflammation 
OXIDATIVE 
STRESS 
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Pathophysiology: 
 The above described pulmonary pathologies produce a number of 
physiologic abnormalities. They are 
a) Mucus hypersecretion 
b) Ciliary dysfunction 
c) Airflow limitation 
d) Hyperinflation 
e) Abnormalities in gas exchange 
f) Pulmonary hypertension 
g) Systemic effects 
 
Mucus hypersecretion& ciliary dysfunction63: 
 Mucus hypersecretion culminates in chronic cough which is productive 
in nature.Airflow limitation is not a sine qua non of chronic bronchitis and 
similarly chronic productive cough is not present in all patients with COPD. 
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Airflow limitation & Hyperinflation: 
Decrease in maximum expiratory flow is the characteristic physiological 
abnormality in COPD64,65. Increase in airway resistance and loss of lung 
elasticity are the major contributors to the subnormal maximum expiratory 
flow. 
  In healthy young individuals significant airway closure occurs below 
functional residual capacity. COPD is characterised by enhanced airway 
closure at higher lung volumes in the early stages. 
  
CILIARY DYSFUNCTION 
SQUAMOUS METAPLASIA SUBMUCOSAL GLAND 
HYPERTROPHY 
INCREASED GOBLET CELL 
NUMBER 
CIGARETTE SMOKE 
MUCUS 
HYPERSECRETION 
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SETTING CLOSING VOLUME 
Normal young nonsmoker 5-10% of VC 
Old age 25-35% of VC 
Young asymptomatic smokers                      Increased 
 
 Small conducting airways are the main site of airflow limitation in 
COPD. Inflammatory exudates and airway narrowing due to remodelling are 
the major causes for this airflow limitation. Loss of elastic recoil of the lung 
and alveolar support destruction are other factors that contribute to airflow 
limitation. 
Airway obstruction 
 
Progressive air trapping (during expiration) 
 
Hyperinflation (at rest) & Dynamic hyperinflation66(at exercise) 
 
Increased FRC 
 
Dyspnoea & limited exercise capacity 
 The carbon monoxide transfer factor (TLCO) is mostly reduced in 
advanced COPD since there is a reduction in ventilated lung volume due to 
uneven distribution of ventilation. 
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Gas exchange abnormalities: 
In COPD, the most important aetiology of impaired gas exchange is the 
ventilation – perfusion mismatching67. Other minor factors that contribute to 
impaired gas exchange are increased shunt, impaired alveolar- capillary 
difference to oxygen and alveolar hypoventilation. With disease progression 
there is worsening of gas exchange. There is uneven distribution of 
ventilation in COPD patients.  
 The factors which contribute to reduced blood flow are 
a) Local destruction of alveolar wall vessels 
b) Hypoxic vasoconstriction 
c) Passive vascular obstruction 
 These factors cause a V/Q mismatch. Impaired function of ventilatory 
muscles in severe COPD and the V/Q mismatch results in reduced ventilation 
and CO2 retention. 
 
Impaired respiratory muscle function: 
 In severe COPD there is a reduced respiratory muscle capacity due to 
muscle weakness68. Muscle weakness is caused by lung overinflation and 
malnutrition. Increase in airway resistance contributes to the increase in load 
against which the respiratory muscles have to act. Lung overinflation results 
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in shortening and flattening of the diaphragm thus reducing it’s ability to 
lower pleural pressure. 
 In normal individuals, expiration is mostly a function of elastic recoil 
of the lungs during quiet tidal breathing. COPD patients need to use their rib 
cage muscles and accessory inspiratory muscles for this purpose. This pattern 
could be further worsened during exertion leading to a paradoxical rib cage 
motion. 
 
Pulmonary hypertension: 
Pulmonary arterial hypertension is a late feature of COPD when there is 
severe hypoxemia and hypercapnia51,52.  
 The factors causing PAH are 
a) Endothelial dysfunction 
b) Pulmonary arterial constriction 
c) Destruction of pulmonary capillary bed 
 PAH causes right ventricular hypertrophy and dysfunction. 
Corpulmonale due to COPD carries a poor prognosis. 
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Systemic effects of COPD: 
Although COPD is primarily a pulmonary disease, severe COPD is 
punctuated by an array of systemic effects69,70. They are 
a) Skeletal muscle wasting 
b) Cachexia 
c) Increased cardiovascular risk 
d) Osteoporosis 
e) Normocytic normochromic anaemia 
 These systemic effects could be mediated via reactive oxygen species, 
IL-6 and TNF α. 
 
Pathophysiology of COPD exacerbation: 
 COPD exacerbations augment the pulmonary inflammation. 
Neutrophilic inflammation is predominant. There may be an increased 
number of eosinophils in mild exacerbations. Reactive oxygen species and 
factors like TNFα, IL-8, LTB4 play a role in these exacerbations. 
 Airflow limitation is unchanged in mild exacerbations whereas in 
severe exacerbations are associated with increased V/Q mismatch and fatigue 
of respiratory muscles71. These changes can precipitate respiratory acidosis, 
respiratory failure, corpulmonale and even death. 
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Clinical history: 
When to suspect COPD? 
 COPD should be suspected in any individual > 35 years with 
complaints of chronic cough, breathlessness, recurrent respiratory infections, 
sputum production, impaired exercise tolerance with/without history of risk 
factors. The diagnosis should be confirmed using spirometry. 
Symptoms: 
- Breathlessness ( on exertion +/- wheeze & cough ) 
- Productive cough ( 50 % ) 
- Chest pain ( GORD / Ischaemic heart disease/ 
Exacerbation of COPD ) 
- Anorexia & weight loss 
- Depressed mood 
- Other important historical points : fatigue, nocturnal 
awakening, occupational hazards, ankle swelling, family 
history 
There are scales to assess dyspnoea such as modified Borg scale      (min-
0;max-10 ) and modified MRC dyspnoea scale ( min-0; max-5 ). 
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Clinical examination: 
 Physical signs are not specific. They depend on the degree of lung 
overinflation and airflow limitation. Absence of physical signs does not 
exclude COPD. 
General examination: 
- Tachypnoea at rest 
- Breathing pattern:  prolonged expiration, pursed lip 
breathing 
- Use of accessory muscles 
- Cyanosis ( advanced disease ) 
- Flapping tremor ( hypercapnia ) 
- Muscle wasting 
- Tar stained fingers ( smoking ) 
Chest Examination: 
- Barrel shaped chest: kyphosis, horizontal ribs, sternal 
angle prominence, wide subcostal angle, apparent 
increase of A-P diameter. 
- Inspiratory tracheal tug 
- Hoover’s sign: Inward movement of lower ribs due 
horizontal position of diaphragm 
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- Percussion: decreased cardiac and hepatic dullness ( 
overinflation ) 
- Breath sounds: increased expiratory phase or diminished 
breath sounds , wheeze ( both inspiratory and expiratory 
), crackles may be heard in lung bases 
Cardiovascular examination: 
- JVP: difficult to localise, prominent ‘V’ wave ( 
functional Tricuspid Regurgitation ) 
- Difficulty in localising apex beat 
- Parasternal heave ( PAH ) 
- Heart sounds: generally soft , Loud P2 ( PAH ) , S3 
gallop 
 
Investigation of respiratory function and exercise capacity: 
 In COPD, obstruction to forced expiratory airflow is the most 
important respiratory disturbance. 
1) Spirometry: 
 This is the most vigorous test of airflow limitation in COPD patients72. 
The test is highly effort dependent. Hence maximum effort by the patient 
must be ensured. The measurements obtained during the test are evaluated by 
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comparing with appropriate references based on age, sex, height and race. 
The spirometry criteria for COPD is 
 
 
 
2) Reversibility testing73: 
 This helps to differentiate COPD from asthma. Performing this test is 
useful for predicting survival in COPD patients since the best predictor of 
survival is the post bronchodilator FEV1. Although there is no consensus on 
the standard method of reversibility testing, it can be recorded as a change in 
FEV1 or peak expiratory flow. A suggested protocol for reversibility testing is 
 
 
 
 
 
 
 
 
1. Post Bronchodilator FEV1 < 80% predicted 
2. FEV1/FVC < 0.7 
1. 2.5 mg nebulised salbutamol / 400µg salbutamol via   
metered dose inhaler          FEV1 improves by 15% and 
200 ml after 20 minutes. 
2. 30 mg prednisolone for 2 weeks         FEV1 
improves by 15% and 200 ml. 
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DISEASE SEVERITY IN COPD: 
 
a) NICE guidelines: 
SEVERITY FEV1( % predicted ) FEV1/FVC ( % ) 
Stage 1 ( mild ) 50 - 80 < 70 
Stage 2 ( moderate ) 30 - 49 < 70 
Stage 3 ( Severe ) < 30 < 70 
 
 
 b) GOLD criteria: 
SEVERITY FEV1 ( % predicted ) FEV1/FVC ( % ) 
Stage 1 ( mild ) ≥ 80 < 70 
Stage 2 ( moderate ) 50 - 79 < 70 
Stage 3 ( severe ) 30 - 49 < 70 
Stage 4 ( very severe ) < 30 < 70 or < 50 plus 
chronic respiratory 
failure 
 
 
3) Flow volume loops74: 
 Airflow has been measured using expiratory flows at 75% / 50% of  
VC ( vital capacity ). These measurements are less reproducible when 
compared to spirometry and not much of use in clinical settings. 
44 
 
 
4) Peak expiratory flow: 
 There are two methods to assess peak expiratory flow75 
a) Handheld peakflow meter 
b) Flow volume loops 
Peak expiratory flow is particularly useful in asthma whereas in COPD it 
may underestimate the degree of airflow limitation. 
 
5) Lung volumes: 
 The degree of pulmonary overinflation and air trapping can be assessed 
by measuring the static lung volumes which include FRC ( functional 
residual capacity ), RV ( residual volume ), TLC ( total lung capacity ).  
 The methods by which static lung volumes can be measured are 
a) Helium dilution technique – may underestimate lung  
volumes 
b) Body plethysmography – higher lung volume readings 
than 
          Helium dilution method 
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6) Gas transfer for carbon monoxide (TLCO): 
 Many COPD patients have a low TLCO. The TLCO and the extent of 
emphysema are related to each other. Despite the above relationship, 
emphysema severity cannot be predicted from TLCO. Further, a low TLCO is 
not specific for emphysema. Single breath technique is the commonly used 
method for assessing TLCO76. 
 
7) Arterial blood gases: 
 In COPD patients, arterial blood gases are required for confirming the 
degree of hypercapnia and hypoxaemia.  
 Indications for ABG are 
a) stable patients with FEV1< 50% predicted 
b) clinical evidence of respiratory failure 
c) Right heart failure 
 Pulse oximeter is used for hypoxaemia screening. If SpO2<92, 
measurement of arterial blood gases becomes necessary. 
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8) Exercise testing: 
 There is an increase in O2 consumption and production of CO2 during 
exercise. In 40% of COPD patients exercise capacity is limited by dyspnoea. 
There are three forms of exercise testing77,78.  
They are 
a) Progressive symptom limited exercise 
b) Self paced exercise 
c) Steady state exercise 
 
9) Tests of respiratory muscle function: 
                       Maximum mouth pressures are the routine respiratory muscle 
function tests in COPD patients. In COPD patients, there is impairment of 
maximum inspiratory pressures due to hyperinflation & abnormal breathing 
mechanics. The maximum expiratory pressure is reduced due to muscle 
weakness. 
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10) Sleep studies: 
 There is hypoxaemia during sleep , especially REM sleep in COPD 
patients79. Nocturnal hypoxaemia measurements are not of much value unless 
there is a suscpicionof  sleep apnoea syndrome. 
BODE index: 
 It is a composite score. With increasing BODE index score there is 
increased risk of respiratory failure and death. 
PARAMETER 0 1 2 3 
FEV1 
(% predicted) 
≥65 50-64 36-49 ≤35 
6 minute walk 
distance( m ) 
≥350 250-349 150-249 ≤149 
MRC scale 0-1 2           3 4 
BMI ≥21 ≤21   
 
11) Other routine tests: 
                   - Complete blood count: anaemia of chronic disease, 
polycythemia 
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                   - α1-antitrypsin levels & phenotype: family history of emphysema 
at young age ; COPD < 45 years of age. 
IMAGING: 
 
1) Plain Chest radiography: 
 The features in CXR PA view are not specific for COPD. The reliable 
signs due to emphysema can be discussed under two headings.  
 They are 
a) Lung Overinflation: low flattened diaphragm, increase in 
retrosternal airspace, obtuse costophrenic angle 
b) Vascular changes: number and size of pulmonary vessels 
are reduced, distortion of vessels, areas of transradiency 
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Chest X-ray showing hyperinflated lung fields 
2) CT chest: 
Assessment of a CT chest in a patient with emphysema reveals 
                      - low attenuation areas without obvious walls or margins 
                       - Vascular tree is attenuated and there is pruning 
                       - Vascular configuration is abnormal 
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CT Chest showing Bullae in right lung 
 
 
 Low attenution is the sign that correlates very well with areas of 
macroscopic emphysema. The disease severity is usually underestimated in 
CT scanning. HRCT can distinguish the various morphological variants of 
emphysema. 
 Density mask technique is more of a quantitative approach by 
highlighting pixels in lung field regions between -910 and -1000 HU. This 
method is useful for assessing macroscopic emphysema. CT lung density is 
used for quantifying microscopic emphysema. It is expressed on a linear 
scale in HU. At present, the most sensitive and specific imaging modality for 
assessing emphysema is CT. 
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3) Imaging in patients with PAH / Corpulmonale: 
- CXR: Right ventricle enlargement/hypertrophy 
 - Echocardiogram: for assessment of PAH 
 - Right heart catheterization: ‘Gold standard’ for assessing PAH 
 
PREVENTION OF COPD: 
 It is well known fact that cigarette smoking is the major culprit in 
causing COPD. Smoking cessation is the single most effective way of 
reducing the risk of COPD. The five A’s in cessation of smoking are ‘Ask’( 
ask about tobacco use ), ‘Advise’ ( advise quitting smoking ), ‘Assess’ ( 
assess willingness to make an attempt ) and ‘Assist’ ( assist in quit attempt ), 
‘Arrange’ ( arrange follow –up ). Many long term smokers develop a 
withdrawal syndrome which results from nicotine craving. The 
manifestations of this syndrome are anxiety, increase in appetite, irritability 
and restlessness. Nicotine gums and nicotine skin patches are useful in these 
circumstances. 
 The incidence of COPD can also be reduced by controlling 
environmental pollution, protection of workers from occupational hazards, 
alleviating poverty and improving socio economic status of the poor. 
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MANAGEMENT OF STABLE COPD: 
 The ideal goals of COPD treatment are 
                        - Symptom relief 
                         - Improving exercise tolerance 
                         - Health status improvement 
                         - retarding disease progression 
                         - Prevention and treatment of complications 
                         - Prevention and treatment of exacerbations 
                         - Mortality reduction 
 
1) Bronchodilators: 
 They are the cornerstones of COPD treatment with regards to symptom 
reduction and improving exercise tolerance. In contrast to Bronchial asthma 
where bronchodilators are highly effective, their effects in COPD are small 
due to structural changes in airways. 
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a) β-Agonists: 
 These drugs cause airway smooth muscle relaxation via the β 
adrenergic receptor – cAMP pathway80,81. Inhaled agents are better compared 
to oral formulations because of higher efficacy at smaller doses and fewer 
side effects. These drugs can be used for symptomatic relief in COPD 
patients because of the relatively fast onset of action. Short acting β-agonists 
are salbutamol, fenoterol and terbutaline. The duration of action of these 
drugs is around 4-6 hours. Long acting β-agonists are formoterol and 
salmeterol. These drugs have atleasta 12 hour duration of action. Adverse 
effects of β-agonist therapy include tachycardia, cardiac rhythm disturbances 
in susceptible individuals and hypokalemia. These effects are less common 
with inhalational therapy. 
 
b) Anticholinergics: 
 These drugs act by blocking the muscarinic actions of acetyl choline82. 
The short acting anticholinergics are ipratropium and oxitropium. They are 
slower than β-agonists (30-60 minutes for peak effect) but have a longer 
duration of action (6-10 hours).Tiotropium is a longer acting anticholinergic 
(duration of action – 24 hours) which can be used once daily. 
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c) Theophyllines: 
 These agents have a modest bronchodilator effect in COPD patients84. 
Their mode of action is still a controversy. They could possibly act as a 
nonselective phosphodiesterase inhibitor83. Theophyllines have a narrow 
therapeutic index (therapeutic range: 10-20 mg/L). Many patients develop 
adverse effects within the therapeutic range. Factors such as hypoxaemia, 
smoking, antibiotics and infection influence theophylline clearance. Thus it is 
very difficult to titrate theophylline levels in COPD. These drugs can be used 
as a last resort in patients whose symptoms are adequately controlled by other 
treatment modalities. Some of the adverse effects of theophyllines are 
vomiting, abdominal pain, diarrhoea, hypokalemia, cardiac arrhythmias and 
seizures. Roflumilast and Cilomilast are selective PDE-4 inhibitors that have 
been recently developed. 
2) Corticosteroids: 
 The rationale for using corticosteroids in COPD is the airway 
inflammation. Their role in COPD is controversial since it is difficult to 
predict treatment response in patients. 
a) Oral corticosteroids: 
 Only 10-20% of stable COPD patients respond to oral corticosteroids. 
It is difficult to predict which patient will respond. Long term corticosteroid 
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therapy can cause myopathy which can worsen respiratory function in COPD. 
Thus oral corticosteroids are not indicated in stable COPD. 
b) Inhaled corticosteroids: 
 Majority of the clinical trials using inhaled corticosteroids have failed 
to show evidence of disease modification in mild to moderate COPD85,86. 
Based on various large scale clinical trials it can be concluded that inhaled 
corticosteroids have a beneficial effect in patients with FEV1< 50% and those 
who experience 2 or more exacerbations per year. 
 Combination therapy (inhaled corticosteroid + long acting β-agonist) 
appears to be more effective than individual components. 
 
3) Other agents: 
a) Vaccines: 
 Influenza vaccine87: can reduce mortality due to influenza in COPD 
patients by 50%. Killed or inactivated virus vaccines are 
recommended. The vaccine is given once a year. 
 Pneumococcal vaccine88: recommended in COPD patients older than 
65 years. It reduces the incidence of community acquired pneumonia in 
patients with very severe disease. 
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b) Antibiotics: 
 There is no conclusive evidence for the use of continuous prophylactic 
antibiotics in COPD. 
 
c) Mucolytic agents: 
 Regular use of mucolytics has some effect in reducing the frequency of 
exacerbations. Carbocisteine and mecysteine hydrochloride are the mucolytic 
agents used in COPD89. These agents can be used in patients who experience 
frequent exacerbations and those who have difficulty in expectorating 
sputum. At present, N-Acetylcysteine is not recommended in COPD 
treatment. 
 
d) Antitussives: 
 Although cough can be a troublesome symptom in some COPD 
patients, regular use of antitussives is not recommended since cough has a 
protective role in this setting. 
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4) Oxygen therapy: 
 Domiciliary oxygen therapy is the only treatment by which long term 
prognosis is improved in COPD patients90. The two major trials conducted on 
domiciliary oxygen therapy are the NOTT (Nocturnal Oxygen Therapy Trial) 
in the USA and the MRC trial (Medical Research Council) in the UK. In the 
MRC trial there was an improvement in five year survival rates from 25 to 
41% among those using oxygen for 15 hours/day (compared with no 
oxygen). Continuous oxygen therapy (mean use – 17.5 hours/day) improved 
survival whereas use of 12 hours/day was of no use according to the NOTT. 
Long term oxygen therapy did not halt or slow the decline in FEV1even 
though FEV1 is the strongest predictor of survival in COPD. 
 The three forms of domiciliary oxygen therapy are 
a) Long term controlled O2 therapy:  
  - given via nasal prongs or masks ;transtracheal route ( 
if there is refractory hypoxaemia ) 
   - 15 hours/day 
   - useful in patients with chronic respiratory failure 
                            b) Ambulatory O2 therapy ( for exercise related hypoxaemia 
) 
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                            c) Short burst O2 therapy ( palliative treatment useful in the  
temporary relief of dyspnoea ) 
Oxygen during air travel: 
 Who are safe to fly without supplemental O2? 
Patients with SpO2> 95% and resting  PaO2 ( at sea level ) > 70 mmHg. 
 
 Who require oxygen while flying? 
Patients on home O2 therapy 
SpO2< 92% 
 
 If 95 > SpO2< 92? 
These patients are vulnerable to desaturation at high altitudes. They 
should be offered a ‘Hypoxic challenge test’. If the PaO2 remains more 
than 55 mmHg, O2 is not usually required. If PaO2 falls below 50 
mmHg, an in-flight O2of 2 litres/min is advised. The remaining cases 
are managed according to clinical judgement. 
 
5) Ventilatory support: 
 NIPPV ( noninvasive positive pressure ventilation ) is not of much use 
in stable COPD patients and in those with chronic respiratory failure. 
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Combination of NIPPV with long term O2 therapy could be useful in select 
patients who experience prolonged daytime hypercapnia. 
6) Pulmonary rehabilitation: 
 Pulmonary rehabilitation is defined as “a multidisciplinary programme 
of care for patients with chronic respiratory impairment that is individually 
tailored and designed to optimize physical and social performance and 
autonomy”. This is very useful in patients with moderate to severe COPD.  
 The components of pulmonary rehabilitation are 
a) Exercise training 
b) Education 
c) Psychosocial and behavioural intervention 
d) Nutritional therapy 
 The benefits of pulmonary rehabilitation91 are  
a) Reduction of intensity of dyspnoea on exertion 
b) Improvement in exercise tolerance 
c) Improvement in quality of life 
d) Reduction in the number of admission days 
e) Psychological improvement 
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MANAGEMENT OF ACUTE COPD EXACERBATIONS: 
 Sustained worsening of symptoms is a characteristic of COPD 
exacerbations. Frequent exacerbations lead to an accelerated decline in lung 
function. 
 
Assessment of severity: 
 The severity of COPD exacerbation can be assessed by comparing 
previous medical history with the presenting symptoms. Spirometry is 
inaccurate in this setting. Pulse oximeter is useful to assesss the need for 
supplemental O2. Chest X ray should be obtained to rule out alternative 
diagnosis such as bronchopneumonia, pneumothorax and pulmonary oedema. 
 
Oxygen therapy: 
 This forms a vital part in the management of severe COPD 
exacerbations. The aims of O2 therapy is to maintain a PaO2>60 mmHg and 
SpO2> 90 mmHg. Blood gases are checked 30-60 minutes after initiating O2 
therapy to assess the adequacy of treatment. 
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Bronchodilators: 
 Nebulized bronchodilators should be given at 4-6 hour intervals. β-
agonists such as salbutamol 2.5-5 mg or an anticholinergic such as 
ipratropium 0.5 mg are used.  
 Intravenous methylxanthines can be used if the patient does not 
respond to bronchodilators. Aminophylline is used as a loading dose of 6 
mg/kg followed by maintenance of 0.5 mg/kg/hour. 
 
Antibiotics92: 
 COPD exacerbations are commonly precipitated by infections. The 
recommended broad spectrum antibiotics are amoxicillin (250 mg TDS PO) 
or clarithromycin (250-500 mg BD PO) in case of penicillin allergy. 
 
Respiratory stimulants: 
 The role of doxapram in COPD93 has diminished since the introduction 
of non invasive ventilation. If non invasive ventilation is not available or is 
contraindicated, intravenous doxapram infusion can be used. The usefulness 
of doxapram is limited by its adverse effects such as tachycardia and 
hallucinations. 
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Diuretics:  
 These drugs should be carefully titrated to avoid overdiuresis which 
can result in cardiac output reduction by reducing right ventricular end 
diastolic volume. 
 
Anticoagulants: 
 In patients with severe COPD, pulmonary emboli go under 
recognized94. CT pulmonary angiogram is the imaging modality of choice in 
this setting since V/Q scans can lead on to false positive results. Prophylactic 
LMW heparin is given subcutaneously in COPD exacerbations, particularly if 
there is respiratory failure. 
 
Physiotherapy: 
 Physiotherapy has little or no role in COPD exacerbations. 
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SURGICAL TREATMENT OF COPD: 
Bullous emphysema: 
The various presentations of bullae are  
 Chance finding in CXR 
 Pneumothorax 
 Infection with consolidation 
 The usual presenting symptom is exertional dyspnoea. Surgical 
obliteration is the only possible treatment for large bulla95. The aims of 
surgery are 
 Bullous space obliteration 
 To restore lung elasticity 
 Some of the techniques used are intracavitary drainage, plication, 
marsupialization and excision. Most procedures are done via conventional 
lateral thoracotomy.Best results are achieved in young patients with a large 
bulla and normal surrounding lung. 
 
Lung volume reduction surgery: 
 The rationale for this procedure is reduction in the volume of 
emphysematous lung. The NETT (National Emphysema Treatment Trial 
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)compared medical treatment with LVRS in emphysema patients. This study 
showed superior survival rates in the LVRS arm compared to the medical 
treatment arm. 
 
Lung Transplantation: 
 This procedure can be performed in carefully selected very severe 
COPD patients. Although it improves quality of life and functional capacity, 
there is no survival benefit beyond 2 years in endstage emphysema. 
 
THE TESTES: 
 The testes are paired endocrine organs in males. They are the major 
source of testosterone. The shape of adult testis is prolate spheroid. The mean 
volume of testis is about 18.6 +/- 4.8 ml.  
The two major components of testis are 
 Leydig cells (Interstitial cells): This is the main endocrine component 
of the testis. Testosterone is the principal secretory product of these 
cells. Testosterone is responsible for embryonic differentiation along 
male lines, secondary sexual character development in males and 
maintenance of libido and potency. 
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 Seminiferous tubules: They form the testis bulk. These tubules produce 
spermatozoa. 
 
Gonadal Steroids: 
 The most important steroids associated with male reproductive 
function are 
a) Testosterone 
b) Dihydrotestosterone 
c) Oestradiol 
 
HORMONE SECRETION 
FROM 
TESTIS 
SECRETION 
FROM 
ADRENALS 
PRECURSOR 
CONVERSION 
IN 
PERIPHERIES 
Testosterone 95% <1% <5% 
Dihydrotestosterone <20% <1% 80% 
Oestradiol <20% <1% 80% 
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Testosterone biosynthesis: 
Cholesterol        Pregnenolone                         Progesterone 
 
                     17α-OH pregnenolone              17α-OH progesterone 
 
Dehydroepiandrosterone            Androstenedione          Oestrone 
 
                      Androstenediol     Testosterone      Oestradiol 
 
      Dihydrotestosterone 
 
Testosterone metabolism: 
 The major site of testosterone metabolism is the liver. Testosterone is 
converted into etiocholanolone and androsterone. These metabolites are 
conjugated with sulphuric acid and glucuronic acid and undergo urinary 
excretion as 17-ketosteroids. Some amount of the hormone is converted into 
dihydrotestosterone. 
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Control of testosterone secretion: 
 
The hypothalamic – pituitary – leydig cell axis: 
 GnRH (Gonadotropin releasing hormone) is a decapeptide secreted 
from the hypothalamus in a pulsatile manner (every 30-120 min). It acts on 
the pituitary gonadotrophs and stimulates LH (Luteinizing Hormone) release 
mainly and FSH (Follicle Stimulating Hormone) to a lesser extent. LH enters 
the general circulation and reaches the testis. It acts on the leydig cells 
resulting in cAMP generation and StAR synthesis. The end result is increased 
testosterone synthesis. The androgens have negative feedback control on 
moth hypothalamus and pituitary. 
 
Male Hypogonadism: 
Male hypogonadism is a “ clinical syndrome that results from a failure of the 
testis to produce adequate amounts of testosterone; this is almost always 
associated with impaired sperm production or with an isolated impairment of 
sperm production or function with normal testosterone production”. 
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Classification of male hypogonadism: 
1) Hypothalmic pituitary disorders: 
- Panhypopituitarism 
- Isolated FSH deficiency 
- Isolated LH deficiency 
- FSH & LH deficiency ( Kallmann syndrome, Prader-
Willi syndrome, Lowe Syndrome, Mobius syndrome, 
Cerebellar ataxia, Lawrence – Moon – Biedl syndrome ) 
- Hyperprolactinaemia 
- Biologically inactive LH 
2) Gonadal disorders: 
- Chromosomal defects: XX male, XX/XXY, XY/XXY, 
XXXY, XXXXY, XXYY, XYY  
- Klinefelter syndrome 
- Vanishing testes syndrome 
- Cryptorchidism 
- Leydig cell aplasia 
- Noonan syndrome 
- Adult seminiferous tubule failure 
- Myotonic dystrophy 
- Androgen biosynthesis defects 
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- Adult leydig cell failure 
3) Defects in androgen action: 
- Testicular feminization syndrome 
- Incomplete androgen insensitivity 
 
Clinical features of adult hypogonadism: 
 Male hypogonadism is diagnosed in individuals with clinical features 
of androgen deficiency and low serum levels of testosterone. Prevalence of 
low testosterone levels are higher than symptomatic androgen deficiency 
among middle to old aged males. The predominant symptoms of androgen 
deficiency are decreased libido, erectile dysfunction, fatigue, depressed mood 
and sleep disturbances. The risk of diabetes mellitus and cardiovascular 
events are also increased in this setting. Hypogonadism is diagnosed in men 
who exhibit clinical features of androgen deficiency by demonstrating 
consistently low serum levels of serum testosterone103. 
 
Testosterone measurements: 
Serum testosterone levels show both assay and biological variability. There 
must be consistent and unequivocal evidence of low serum testosterone levels 
for the diagnosis of androgen deficiency. The exact thresholdof serum 
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testosterone level at which symptoms of androgen deficiency occur are not 
known. However a level of 280-300 ng/dl can be used when testing done by 
an accurate and reliable assay. 
 
Variability in serum testosterone levels: 
 Circadian and ultradian variations are exhibited by serum testosterone 
levels. Peaking of circadian variation occurs at about 8 am. This excursion is 
blunted in old age (approx. 60 ng/dl) when compared to younger individuals 
(approx. 140 ng/dl). Further, the testosterone level is 20-25% lower at 4 pm 
when compared to 8 am in younger individuals. In older men, the levels are 
approximately 10% lower at 4 pm when compared to 8 am. Considering these 
variations, testosterone levels are best measured in the morning. 
 Day to day variation in testosterone levels are also significant. In a 
study, 30% of the men who had initial testosterone levels less than 300 ng/dl 
had normal testosterone levels on subsequent testing. These factors 
emphasize the importance of repeat measurements of serum testosterone 
levels. 
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Total testosterone assays: 
 These assays are generally readily available. The recommended initial 
measurement of androgen deficiency is total testosterone levels. There are 
wide variations among various laboratories due to inadequate quality control. 
Liquid chromatography - tandem mass spectrometry is an accurate method of 
measuring testosterone. A variety of clinical settings such as diabetes 
mellitus, chronic kidney disease, and HIV infection, moderate to severe lung 
disease are associated with low testosterone levels99. Total testosterone levels 
are influenced by SHBG (Sex Hormone Binding Globulin) levels since about 
30-40% of testosterone in circulation is bound to SHBG. 
Low SHBG concentration High SHBG concentration 
- Moderate obesity 
- Type 2 diabetes mellitus 
- Acromegaly 
- Hypothyroidism 
- Nephrotic syndrome 
- Glucocorticoids, androgens & 
Progestins 
- Familial SHBG deficiency 
- Aging 
- Oestrogens 
- HIV 
- Anticonvulsants 
- Hyperthyroidism 
- Cirrhosis & Hepatitis 
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 Conditions that decrease SHBG levels tend to decrease total 
testosterone levels. In these conditions, free testosterone levels should be 
measured. Equilibrium dialysis or centrifugal ultrafiltration is the gold 
standard method for measuring free testosterone levels. Automated platform 
– based analogimmunoassays for free testosterone measurement is affected 
by changes in SHBG. Hence they are inaccurate and not useful clinical 
settings. 
 Testosterone levels can be suppressed transiently by certain conditions 
such as critical illness, high dose glucocorticoids and CNS- active drugs. 
These factors should be taken into consideration while interpreting serum 
testosterone levels. 
 
Testosterone replacement therapy: 
 A variety of preparations are available for treating androgen deficiency 
a) Sublingual or oral : Methyltestosterone, Oxymetholone,    
Fluoxymesterone 
b) Oral: Testosterone propionate 
c) Intramuscular: Testosterone enanthate, Testosterone cypionate,  
                         Testosterone undecanoate 
d) Subcutaneous implantation: Testosterone pellets 
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e) Transdermal: Testosterone patch 
f) Local application: 1% testosterone gel, buccal preparation ( Striant ) 
These preparations are contraindicated in prostatic carcinoma. 
 
Adverse effects: 
- Intrahepatic cholestasis with methyltestosterone and 
fluoxymesterone 
- Premature epiphyseal fusion 
- Hypertension, CCF 
- Erythrocytosis 
- Oligospermia 
- Priapism 
- Sleep apnoea 
- Acne 
- Aggressive behaviour 
- Decreased HDL levels 
Testosterone levels in COPD: 
 Low serum testosterone levels are common in male COPD 
patients97,98,101,104-108. The prevalence of low testosterone levels vary widely 
according to the population studied. Low or low – normal gonadotropin 
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levels are found in 75% of the male COPD patients with low testosterone 
levels96. The remaining patients have primary hypogonadism with elevated 
gonadotropin levels100. 
 The coexistent features that are common in hypogonadal male COPD 
patients are muscle wasting & cachexia, glucocorticoid usage and hypoxia. 
Hypoxia can suppress both gonadotropin and testosterone secretion. 
 Testosterone replacement therapy has been tried in male COPD 
patients with low testosterone levels. This treatment strategy improved lean 
body mass but fails to improve endurance and quality of life102. 
 
 
 
 
 
 
 
 
 
  
 
 
 
METHODOLOGY 
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METHODOLOGY 
Setting: 
 This study was done at the Institute of Internal Medicine, Madras 
Medical College. All patients were either already inpatients or were admitted 
for conducting the study. 
Study design: 
 Single center cross sectional study 
Study period: 
  July - September 2014 
Collaborating departments: 
 The Institute of Thoracic Medicine was crucial to this study. This 
department served as a source of a substantial proportion of cases. It also was 
the site for doing spirometry for the patients enrolled in the study. 
 Various other departments helped in doing this study. The Cardiology 
department helped in performing echocardiogram for the patients. The 
services of Barnard Institute of Radiology were utilized for imaging 
purposes. The Institute of Biochemistry played an important role by 
performing various biochemical tests. 
76 
 
Selection of subjects: 
 Male COPD patients of   ≥40 years of age with disease duration  ≥ 5 
years were analysed. Out of the 148 patients analysed, 48 patients were 
excluded from the study according to the proposed exclusion criteria. 
 
 
Diabetes Mellitus - 21 
Chronic Kidney Disease – 9    EXCLUSION CRITERIA 
Congestive Cardiac failure - 6  
Cirrhosis of liver - 5 
HIV infection - 2 
Acutely ill patients - 5 
 
 
Inclusion Criteria: 
1) Male COPD patients 
2) Age ≥ 40 years 
3) Duration of  disease ≥ 5 years 
 
Total number of patients analysed: 148 
Sample Size: 100 
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Exclusion Criteria: 
1) Diabetes Mellitus 
2) Chronic Kidney Disease 
3) Congestive Cardiac Failure 
4) Cirrhosis 
5) Obesity 
6) Thyrotoxicosis 
7) HIV infection 
8) Acutely ill patients 
Details of study subjects: 
Demography: 
 The subjects who underwent this study were mostly from the northern 
districts of  Tamil Nadu and the neighbouring state Andhra Pradesh. 
Study details: 
 The patients who were analysed prior to enrolment underwent a 
thorough history taking and clinical assessment. They were either inpatients 
already or were admitted for further assessment. 
 They underwent various biochemical tests and imaging studies. 
Exclusion criteria were strictly applied in this study. 
78 
 
1) Diabetes Mellitus: Fasting Blood Sugar ≥ 126 mg/dl or Post 
prandial Blood Sugar ≥ 200 mg/dl or both 
2) Chronic Kidney Disease: Ultrasonographic evidence of small 
echogenic kidneys or Calculated Glomerular Filtration rate as per 
Cockroft – Gault formula < 90 ml/min/1.73 m2 or both with or 
without proteinuria 
3) Congestive cardiac failure: Clinical evidence of volume overload 
status with echocardiographic evidence of biventricular 
dysfunction 
4) Cirrhosis: Ultrasonographic evidence of contracted liver with 
altered echoes with or without clinical evidence of volume 
overload status/Liver cell failure 
5) Obesity: Body mass index ≥ 30 Kg/m2 
6) Thyrotoxicosis: Clinical features of  Hyperthyroidism or 
laboratory evidence of hyperthyroidism( Serum free T4> 1.86 
ng/dl and Serum TSH> 4 mU/L ) 
7) HIV infection: Positive for HIV-1 or HIV-2 ELISA 
8) Acutely ill patients: COPD patients with acute exacerbation 
requiring ventilator support 
 After exclusion of the above mentioned patients, the remaining patients 
were questioned regarding symptoms suggestive of hypogonadism and they 
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OBSERVATION AND RESULTS: 
 The study group included 100 patients. Low testosterone levels were 
found in 34 of the 100 male COPD patients studied. 
1) Age Distribution: 
 
AGE GROUP 
( YEARS ) 
NO. OF 
PATIENTS 
PERCENTAGE 
45-50 20 20 
51-55 30 30 
56-60 36 36 
61-65 8 8 
66-70 5 5 
71-75 1 1 
 
 The above table depicts the age distribution of the patients enrolled in 
this study. All the patients were more than or equal to 45 years of age. The 
age interval 56-60 had the highest number of patients (36). 
 
 
81 
 
 
 
 
Age distribution 
 
 
 
 
 
 
 
0
5
10
15
20
25
30
35
40
45-50 51-55 56-60 61-65 66-70 71-75
82 
 
2) Number of patients in each GOLD stage: 
 
 
 
 The above table shows the number of patients in each GOLD 
stage. There is a fairly even distribution of patients across all stages 
with stage III housing the highest number of patients. 
 
Patient distribution across GOLD stages 
 
 
0
5
10
15
20
25
30
35
GOLD I GOLDII GOLD III GOLD IV
GOLD STAGE NO. OF PATIENTS ( % ) 
I 18(18) 
II 24(24) 
III 30(30) 
IV 28(28) 
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3) GOLD stage distribution in the age interval 45-50 years: 
PARAMETER GOLD STAGE 
I II III IV 
Count 8 7 4 1 
% Within age 
interval 
40 35 20 5 
%Within 
GOLD stage 
44.4 29.2 13.3 3.6 
 
 Majority of the patients in the age interval of 45-50 years in this 
study fell within GOLD stage I. Also, patients in this age interval 
formed a major part of the total GOLD I population in this study. 
 
4) GOLD stage distribution in age interval 51-55 years: 
PARAMETER GOLD STAGE 
I II III IV 
Count 5 9 8 8 
% Within age 
interval 
16.7 30 26.7 26.7 
% Within 
GOLD stage 
27.8 37.5 26.7 28.6 
 
 In this age interval, the patients are more or less evenly spread 
across all GOLD stages with a slight tilt towards GOLD stage II. 
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5) GOLD stage distribution in age interval 56-60 years: 
 
PARAMETER GOLD STAGE 
I II III IV 
Count 4 6 11 15 
% Within age 
interval 
11.1 16.7 30.6 41.7 
% Within 
GOLD stage 
22.2 25 36.7 53.6 
 
 More than half of the cases in this age interval belonged to 
GOLD stage IV. Conversely, more than half of the GOLD stage IV 
patients in this study were from this age interval. 
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6) GOLD stage distribution in age interval 61-65 years: 
 In this age interval, there were only eight patients. Half of the 
patients came under GOLD stage III in this age interval. 
PARAMETER GOLD STAGE 
I II III IV 
Count 0 2 4 2 
% Within age 
interval 
0 25 50 25 
% Within 
GOLD stage 
0 8.3 13.3 7.1 
 
 The remaining two age intervals of 66-70 and 71-75 had only five and 
one patient respectively. Half the patients of these two age intervals 
combined belonged to GOLD stage III. 
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AGE DISTRIBUTION ACROSS GOLD STAGES 
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7) Serum Testosterone levels in the age interval 45-50 years: 
 
PARAMETER SERUM TESTOSTERONE 
< 280 ng/dl ≥ 280ng/dl 
Count 2 18 
% Within age 
interval 
10 90 
% Within serum 
testosterone 
levels 
5.9 27.3 
 
 In this age interval 90% of patients had normal testosterone 
levels. Individuals in this age interval made up more than one fourth of 
the individuals in this study with normal testosterone levels. 
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8) Serum Testosterone levels in the age interval 51-55 years: 
 
PARAMETER SERUM TESTOSTERONE 
<280 ng/dl ≥ 280 ng/dl 
Count 13 17 
% Within age interval 43.3 56.7 
% Within Serum 
testosterone levels 
38.2 25.8 
 
 Patients in this age interval make up more than one third of the 
patients with low testosterone levels. The prevalence of low 
testosterone levels in this age interval is just above 40% in this study. 
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9) Serum Testosterone levels in the age interval 56-60 years: 
 
PARAMETER SERUM TESTOSTERONE 
< 280 ng/dl ≥ 280 ng/dl 
Count 15 21 
% Within age interval 41.7 58.3 
% Within serum 
testosterone levels 
44.1 31.8 
 
 Patients in this age interval make the highest contribution to the 
group with low testosterone levels in this study. 
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10)  Serum Testosterone levels in the age interval 61-65 years: 
 Half of the patients in this age interval fell in each of the two 
testosterone groups. 
 Surprisingly, the remaining patients in the age intervals 66-70 and 71-
75 fell into the normal testosterone group. Since they are only six in number, 
no conclusion can be drawn from this data. 
PARAMETER SERUM TESTOSTERONE 
< 280 ng/dl ≥ 280 ng/dl 
Count      4        4 
% Within age interval     50       50 
% Within serum 
testosterone levels 
    11.8      6.1 
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AGE AND TESTOSTERONE LEVEL 
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11) Comparison of glucocorticoid treatment and GOLD stage: 
 
GLUCOCORTICOID 
TREATMENT 
PARAMETER GOLD STAGE 
I II III IV 
Present Count 0 6 11 17 
% Within GOLD 
stage 
0 25 36.7 60.7 
Absent Count 18 18 19 11 
% Within GOLD 
stage 
100 75 63.3 39.3 
 
 Among the 100 patients enrolled in the study 34 patients were on long 
term glucocorticoid therapy. Patients who had received inhalational or 
intravenous steroids only during exacerbations and not on regular treatment 
were not considered as patients on glucocorticoid treatment. Majority of the 
patients on long term glucocorticoid therapy were within GOLD stage IV. All 
the patients in GOLD stage I were not on corticosteroid therapy. 
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12) Comparison of glucocorticoid treatment and serum testosterone 
levels: 
GLUCOCORTICOID 
TREATMENT 
PARAMETER SERUM 
TESTOSTERONE 
<280 ng/dl ≥ 280 ng/dl 
Present Count 25 9 
% in patients on 
treatment 
73.5 26.5 
Absent Count 9 57 
% inpatients not 
on treatment 
13.6 86.4 
 
                   Pearson Chi-Square test: p value: < 0.001( highly significant ) 
 Approximately three fourth of the patients on long term glucocorticoid 
treatment had low testosterone levels in this study. The association between 
long term glucocorticoid treatment and low testosterone levels is highly 
significant as per the calculated p value. 
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13) Comparison between body mass index and GOLD stage: 
BMI  
( Kg/m2) 
PARAMETER GOLD STAGE 
I II III IV 
< 20 Count 8 14 14 24 
% Within low 
BMI group 
13.3 23.3 23.3 40 
20-25 Count 10 10 16 4 
% Within low 
BMI group 
25 25 40 10 
 
           Pearson’s Chi-Square test: p value: 0.008 (< 0.01, highly significant) 
 Of the 100 enrolled patients, 60 had low BMI. Among the patients with 
low BMI, 40% fell within GOLD stage IV. Among the 40 patients with 
normal BMI, majority (40%) fell within GOLD stage III. 
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14) Comparison between body mass index and serum testosterone: 
BMI ( KG/M2) PARAMETER SERUM TESTOSTERONE 
< 280 ng/dl ≥ 280 ng/dl 
< 20 Count 33 27 
% Within low BMI 55 45 
20-25 Count 1 39 
% Within normal BMI 2.5 97.5 
 
Pearson Chi-Square test: p value: < 0.001 (highly significant) 
 More than half of the patients with low BMI had low testosterone 
levels. The p value for this association is < 0.001 and is highly significant. 
However, majority of the patients with normal BMI had normal testosterone 
levels. 
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15) Comparison between SpO2 and GOLD stage: 
SpO2 PARAMETER GOLD STAGE 
I II III IV 
< 90 Count 2 7 23 28 
% within low SpO2 
group 
3.3 11.7 38.3 46.7 
≥ 90 Count 16 17 7 0 
% within normal SpO2 
group 
40 42.5 17.5 0 
 
Pearson Chi-Square test: p value: < 0.001 (highly significant) 
 Among the enrolled patients, 60 had low SpO2. Among these patients 
majority were in GOLD III and IV stages. The p value for this association is 
0.000 (< 0.001). This is highly significant. Thus patients with lower SpO2 had 
more severe COPD. 
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16) Comparison between SpO2 and serum testosterone: 
 
SpO2 PARAMETER SERUM TESTOSTERONE 
< 280 ≥ 280 
< 90 Count 30 30 
% within low SpO2 group 50 50 
≥ 90 Count 4 36 
% within low SpO2 group 10 90 
 
                    Pearson Chi-Square test: p value: < 0.001 (highly significant) 
 Among the 60 patients with low SpO2, 50% had low testosterone 
levels. The p value for this association is highly significant. Thus patients 
with lower SpO2 had greater probability of having low testosterone levels 
compared to those with normal SpO2. 
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17) Comparison between serum testosterone and GOLD stage: 
 
GOLD STAGE PARAMETER SERUM TESTOSTERONE 
< 280 ≥ 280 
I Count 3 15 
% within GOLD I 16.7 83.3 
II Count 5 19 
% within GOLD II 20.8 79.2 
III Count 10 20 
% within GOLD III 33.3 66.7 
IV Count 16 12 
% within GOLD IV 57.1 42.9 
 
Pearson Chi-Square test: p value – 0.012 (significant) 
 From the above table it is clearly demonstrated that as the COPD 
severity increased, the likelihood of having a low testosterone level 
increased. The p value for this association is 0.012 (0.01 > p ≤ 0.05). This is a 
significant association. 
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18) Comparison between GOLD stage and BMI: 
 
GOLD STAGE PARAMETER BMI ( Kg/m2 ) 
< 20 20-25 
I Count 8 10 
% within GOLD I 44.4 55.6 
II Count 14 10 
% within GOLD II 58.3 41.7 
III Count 14 16 
% within GOLD III 46.7 53.3 
IV Count 24 4 
% within GOLD IV 85.7 14.3 
 
        Pearson Chi-Square test: p value: 0.008 (< 0.01, highly significant).  
 Although the percentage of patients with low body mass index in 
GOLD stages I to III are similar, the percentage of patients with low body 
mass index in GOLD IV is quite high (85.7%). Thus there is a tendency for 
low body mass index in very severe COPD patients in this study. 
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19) Comparison between serum testosterone and BMI: 
 
SERUM 
TESTOSTERONE 
PARAMETER BMI ( Kg/m2 ) 
< 20 20-25 
< 280 ng/dl Count 33 1 
% within low 
testosterone group 
97.1 2.9 
≥ 280 ng/dl Count 27 39 
% within normal 
testosterone group 
40.9 59.1 
 
Pearson Chi-Square test: p value < 0.001 (highly significant). 
          Almost all patients with low testosterone levels had low BMI. This is a 
highly significant association as shown by the p value. 
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20) Comparison of disease duration and GOLD stage: 
GOLD STAGE NUMBER OF PATIENTS MEAN DISEASE 
DURATION 
I 18 13.06 
II 24 14.71 
III 30 16.67 
                   IV 28 18.43 
 
ANOVA test: significance 0.000 
      The average disease duration increased from GOLD I to GOLD IV. 
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21) Comparison of disease duration and serum testosterone levels: 
 
SERUM TESTOSTERONE         
( ng/dl ) 
MEAN DISEASE 
DURATION 
< 280                  17.29 
≥ 280                  15.39 
 
 T- test significance : 0.009 
 Average disease duration was higher in the low testosterone group. 
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DISCUSSION 
 Out of the 100 patients enrolled in the study, majority (66%) were in 
the age interval 51-60. Similarly maximum number of patients belonged to 
GOLD III & IV stages (58%). 
 Among the 100 patients, 34 had low testosterone levels. Various 
studies have yielded similar results (Laghi et al 37%). Low testosterone 
levels are more common in very severe COPD patients according to various 
studies104-108. The same trend is seen in this study (57.14% of patients with 
very severe COPD had low testosterone levels). 
 Of the 100 patients, 34 were on long term glucocorticoid treatment. 
Among these patients, 25 had low testosterone levels (73.5%) whereas only 
13.6% among those not taking glucocorticoids had low testosterone levels. 
 Lower BMI was more common in the very severe COPD group. 40% 
of those with low BMI had very severe COPD.This finding was similar to the 
study done by Hsu et al. 
 More than half (55%) of the patients with low BMI had low 
testosterone levels. This is due to the fact that low testosterone levels could 
be one of the contributory factors for muscle wasting in COPD. 
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 Half of the patients in this study with resting hypoxia had lower 
testosterone levels108. Hypoxia induced inhibition of gonadotropin secretion 
is a well known fact. 
 Correlation between low FEV1 and low testosterone levels are 
known104-108. Similarly, in this study GOLD stage IV housed the maximum 
number of patients with low testosterone levels. 
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CONCLUSIONS 
1) Patients in GOLD stage IV had higher probability of having low 
testosterone levels. 
2) Patients had higher risk of low testosterone levels with decreasing 
oxygen saturation. 
3) Patients showed a tendency of decreasing BMI with increasing disease 
severity. 
4) Patients on long term glucocorticoid therapy had higher chances of 
having low testosterone levels. 
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SUMMARY 
 The occurrence of low testosterone levels in COPD has been 
demonstrated by various studies104-108. However the percentage of patients 
having low testosterone levels varies widely among studies. In this study the 
prevalence of low testosterone levels was 34%. 
 The aetiology of low testosterone levels in COPD is multifactorial. 
They are direct effect of smoking on the testis, hypoxia induced inhibition of 
pituitary gonadotropin secretion, direct effect of hypoxia on Leydig cells and 
effect of long term glucocorticoid therapy. 
 The significance of low testosterone levels in COPD lies in the fact 
that it independently increases the mortality in this setting apart from 
affecting the quality of life109. Testosterone replacement therapy has been 
already tried in this setting with encouraging results. Further studies are 
needed in this area for better understanding and for improving therapeutic 
approaches. 
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ANNEXURES 
ABBREVATIONS 
ABG  -  Arterial Blood Gases 
BMI  -  Body Mass Index 
BOLD -  Burden of Obstructive Lung Disease 
cAMP - Cyclic Adenosine Mono Phosphate 
CCF  -  Congestive Cardiac Failure 
CD  -  Cluster Differentiation 
CLIA  -  Chemi- Luminescence Immuno Assay 
COPD -  Chronic Obstructive Pulmonary Disease 
CXR PA -  Chest X-Ray Postero Anterior 
DALY -  Disability Adjusted Life Years 
ELISA -  Enzyme Linked Immuno- Sorbent Assay 
FEV1  -  Forced Expiratory Volume in 1 second 
FRC  -  Functional Residual Capacity 
FSH  -  Follicle Stimulating Hormone 
FVC  -  Forced Vital Capacity 
GOLD  -  Global initiative for chronic Obstructive Lung Disease 
GORD -  Gastro Oesophageal Reflux Disease 
GnRH -  Gonadotropin Releasing Hormone 
HDL  -  High Density Lipoprotein 
HIV  -  Human Immunodeficiency Virus 
HRCT -  High Resolution Computerised Tomography 
HU  -  Hounsfield Unit 
ICU  -  Intensive Care Unit 
IL-6,8& 1β -  Interleukin-6,8 & 1β 
INSEARCH-  Indian Study on Epidemiology of Asthma, Respiratory  
   symptoms and Chronic Bronchitis 
LH  -  Luteinizing Hormone 
LMW  
heparin -  Low Molecular Weight heparin 
LTB4  -  Leukotiene B4 
LVRS -  Lung Volume Reduction Surgery 
MRC  -  Medical Research Council 
NICE  -  National Institute for Health and Clinical Excellence 
NIPPV -  Non Invasive Positive Pressure Ventilation 
PAH  -  Pulmonary Artery Hypertension 
PDE-4 -  Phosphodiesterase-4 
REM  -  Rapid Eye Movement 
RV  -  Residual Volume 
SHBG -  Sex Hormone Binding Globulin 
SPSS  -  Statistical Package for the Social Sciences 
StAR  -  Steroidogenic Acute Regulatory protein 
TGF β -  Transforming Growth Factor β 
TIMP  -  Tissue Inhibitor of Matrix metalloproteinase 
TLC  -  Total Lung Capacity 
TNF  -  Tumour Necrosis Factor 
TSH  -  Thyroid Stimulating Hormone 
UK  -  United kingdom 
USA  -  United States of America 
VC  -  Vital Capacity 
V/Q  -  Ventilation- Perfusion 
YLD  -  Years of Living with Disability 
 
SERUM TESTOSTERONE LEVELS IN MALE  
COPD PATIENTS 
 
Name : Patient ID No: 
Age :      Contact No: 
Occupation  : 
 
Complaints: 
Symptomatics of COPD with 
-erectile dysfunction 
 - poor morning erection 
- loss of ejaculation 
 - low libido 
 
Past history: 
DM, SHT, TB, CAD, CKD, Malignancy, Surgery 
 
Personal history: 
- Smoking 
    - Alcohol 
- Drugs 
 General Examination: 
          Pulse- 
          BP- 
          Height- 
          Weight- 
          BMI- 
          SPO2- 
 
Systemic Examination: 
          CVS- 
          RS- 
          P/A- 
          CNS- 
 
Investigations: 
 
  CXR PA view- 
 
  Pulmonary function test- 
 
  Serum testosterone- 
   FBS- 
  PPBS- 
 
  HIV Elisa- 
 
  Renal function test- 
 
  Liver Function test- 
 
  USG Abdomen- 
 
  ECG- 
 
  Echocardiogram- 
 
  Thyroid profile- 
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